Panelists discuss how evaluating zanubrutinib in combination with obinutuzumab involves considering patient comorbidities, disease characteristics, and previous treatments, with a focus on tolerability, adverse-effect profiles, and patient preferences to guide optimal treatment choices.
Panelists discuss how research on circulating tumor DNA (ctDNA) testing in colorectal cancer requires careful consideration of standardized collection protocols, analytical validation, clinical utility assessment, integration with existing biomarkers, and longitudinal monitoring to establish its role in personalized treatment decision-making.
Panelists discuss how the updated NCCN Guidelines now recommend tazemetostat for the treatment of advanced epithelioid sarcoma, regardless of EZH2 mutation status, based on clinical trial data showing significant clinical benefits and improved progression-free survival in patients with both mutated and non-mutated disease.
Panelists discuss how circulating tumor DNA (ctDNA) testing serves as a complementary tool to traditional imaging in challenging colorectal cancer cases, offering molecular-level insights that can detect disease recurrence earlier, resolve ambiguous radiographic findings, and inform treatment decisions when conventional assessment methods yield inconclusive results.
Workplace burnout in medicine and oncology can lead to stress, exhaustion, fatigue, and a lack of interest in work, according to Eric P. Winer, MD.
Panelists discuss how neoadjuvant and adjuvant therapies, including chemotherapy and radiation, are used in localized epithelioid sarcoma (ES) to optimize surgical outcomes, reduce recurrence risk, and tailor treatment based on tumor characteristics and patient factors.
Panelists discuss how PSMA PET imaging is expected to evolve, enhancing precision in prostate cancer treatment through improved detection and staging. Medical professionals anticipate broader use in therapy guidance, with future advancements addressing gaps in early detection and metastasis, improving treatment strategies.
Panelists discuss how overcoming resistance mechanisms in EGFR-mutated non–small cell lung cancer (NSCLC) remains a key unmet need, with future research focusing on targeting these mechanisms, exploring new drug combinations, and optimizing treatment sequences to improve patient outcomes.
Panelists discuss how the adverse effect profile of amivantamab plus lazertinib (ami-laz) compares with other combination therapies, emphasizing its balance between therapeutic efficacy and quality of life, and how this influences decision-making in treatment selection.
Panelists discuss how, Copper-64 (^64Cu)–labeled PSMA-targeted PET imaging is emerging as a promising modality in prostate cancer diagnosis. The phase 2 SOLAR study (NCT05653856) demonstrated that ^64Cu-PSMA I&T PET/CT effectively detects metastatic prostate cancer, meeting primary end points related to correct localization rates. Compared with gallium-68 (^68Ga) and fluorine-18 (^18F), ^64Cu offers a half-life of approximately 12.7 hours, facilitating centralized production and distribution, which may improve accessibility
Panelists discuss how a real-world case of epithelioid sarcoma (ES) highlights the critical role of early recognition, comprehensive diagnostics including INI1 testing, and a multidisciplinary approach to personalize treatment based on disease extent, tumor location, and molecular features.
Eric P. Winer, MD, said, “[Health care] has a workforce problem, which is part of the reason why we need to embrace nurse practitioners and PAs or APPs.”
Panelists discuss how upcoming studies at ASCO 2025 could change practice in kidney, bladder, and prostate cancer, highlighting research on novel drug combinations, biomarkers, organ-sparing approaches, and AI-driven treatment selection.
Panelists discuss how the evolving landscape of adjuvant therapy in kidney cancer, including targeted therapies and immunotherapy like pembrolizumab, offers curative potential for high-risk patients, with a focus on risk stratification, treatment sequencing, and managing recurrence while weighing benefits and toxicities.
Panelists discuss how first-line chemoimmunotherapy has become the standard for extensive-stage small cell lung cancer (ES-SCLC) based on trials such as IMpower133 and CASPIAN, while emerging agents such as DLL3-targeted therapies show promise in the relapsed setting, highlighting the need for personalized approaches and continued clinical trial participation.
Panelists discuss how major unmet needs in extensive-stage small cell lung cancer—such as lack of durable responses, limited second-line options, absence of predictive biomarkers, and challenges managing brain metastases—underscore the urgency for more effective therapies and comprehensive supportive care strategies.
“Although telehealth is a great thing when used properly, telehealth also puts a barrier between the doctor and the patient,” said Eric P. Winer, MD.
Panelists discuss how the COCOON dermatologic management protocol significantly reduced grade 2 or higher dermatologic adverse events in multiple locations, particularly on the face/body (23% vs 62%), scalp (9% vs 29%), and nails (16% vs 21%).
Panelists discuss how the baseline characteristics of patients in the COCOON trial were evenly matched, with slightly more women than men and a significant number of Asian patients, which is typical for EGFR-mutant non–small cell lung cancer.
Panelists discuss how a thoughtful, individualized approach to third-line treatment in relapsed/refractory follicular lymphoma (R/R FL) involves assessing disease biology, prior treatment responses, and patient-specific factors to guide optimal therapy selection and align with patient-centered goals.
Panelists discuss how adopting a patient-centric approach with comprehensive education about circulating tumor DNA (ctDNA) testing empowers patients with colorectal cancer (CRC) to make informed decisions about their surveillance strategy while advancing personalized care pathways for the future.
Panelists discuss how tumor-informed circulating tumor DNA (ctDNA) testing offers a personalized molecular surveillance strategy that can revolutionize colorectal cancer management through earlier detection of recurrence, real-time monitoring of treatment response, and potential for therapy de-escalation in patients with negative results.
Panelists discuss how treatment in the third-line setting for relapsed/refractory follicular lymphoma (R/R FL) should balance durable disease control with quality-of-life considerations, emphasizing the importance of shared decision-making to align clinical strategies with individual patient goals and preferences.
Findings from clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
“Food is powerful, and [patients] need fuel,” said Claudia Aguilar Clancy, RN, FNP-C, about ensuring patients receive the nutrition they require during cancer treatment.
Panelists discuss how recognizing the diagnostic challenges of epithelioid sarcoma—including its histologic overlap with other conditions and the importance of INI1 loss as a key marker—can improve early detection and reduce misdiagnosis of this rare and aggressive tumor.
Panelists discuss how PSMA PET imaging identified a region of high tracer uptake, guiding medical professionals to implement a focal radiation boost. This approach improved treatment precision and targeting of aggressive areas, highlighting the potential for personalized, effective therapies.
Panelists discuss how targeted cancer therapies, particularly those affecting the EGFR and c-MET receptors, present unique adverse effects such as dermatologic reactions and venous thromboembolism, emphasizing the importance of proactive management, patient education, and evolving treatment strategies to balance efficacy with quality of life.
Panelists discuss how intracranial progression-free survival (PFS) and duration of response (DoR) influence treatment decisions, highlighting the significance of intracranial data in differentiating this regimen within the treatment landscape, its potential impact on brain metastases management, and the role of radiation therapy in clinical practice.
